UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 10, 2019

 

 

SUNESIS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-51531   94-3295878

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

395 Oyster Point Boulevard, Suite 400

South San Francisco, California

  94080
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (650) 266-3500

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol

 

Name of each exchange

on which registered

Common Stock, $0.0001 par value   SNSS   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

 

 

 


Item 2.02.

Results of Operations and Financial Condition.

On a preliminary unaudited basis, Sunesis Pharmaceuticals, Inc. estimates that our cash and cash equivalents as of June 30, 2019 was approximately $17.7 million. The estimate is a preliminary estimate based on currently available information and does not present all necessary information for a complete understanding of our financial condition as of June 30, 2019 or our results of operations for the three and six months ended June 30, 2019.

The information in this Item 2.02 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 shall not be incorporated by reference into any filing with the SEC made by Sunesis, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Item 8.01.

Other Events.

We are filing our July 2019 investor presentation as Exhibit 99.1 to this Current Report on Form 8-K which we intend use from time to time in meetings with stockholders and analysts.

The information contained in the presentation should be considered in the context of our filings with the Securities and Exchange Commission and other public announcements we may make by press release or otherwise from time to time. Information concerning risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission at www.sec.gov.

The presentation speaks only as of the date of this Current Report on Form 8-K and we expressly disclaim any obligation to release publicly any updates or any changes in our expectations or any change in events, conditions, or circumstances on which any forward-looking statement in the presentation is based, except as required by law.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits .

 

Exhibit

    No.    

  

Description

99.1    July 2019 Investor Presentation


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    SUNESIS PHARMACEUTICALS, INC.
Dated: July 10, 2019    
    By:  

/s/ William P. Quinn

      William P. Quinn
      Chief Financial Officer, Senior Vice President,
Finance and Corporate Development
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Sunesis Pharmaceuticals Charts.
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Sunesis Pharmaceuticals Charts.